About Gilead Sciences, Inc.
Gilead generates most of its ~$29B revenue from HIV treatments (Biktarvy dominates), with growing oncology and liver disease franchises. Beta ~0.3, pays ~2.3% dividend. Very low vol for a biotech — behaves more like big pharma. Reliable premium decay for put sellers in stable markets.
Biotechnology — Antiviral & Oncology